American CryoStem recognizes the need for independent testing services as reinforced by the increasing focus and scrutiny of physician office based tissue laboratories by the US Food and Drug Administration (FDA). The menu of testing services includes full 14 day sterility testing, viability testing, growth assay and additional tests for each selected service. The tests can be ordered individually or in multiples over time and are designed to allow physicians to self evaluate their current methods and performance, or to assess new methods or devices designed to improve procedure and tissue quality. Long term and customized programs are available upon request. Physicians enrolled as a provider of the Company’s stem cell storage services can obtain discounts for individual and multi test programs.

“We are very excited about rolling these new services out to our existing providers and all participants in the tissue engraftment, regenerative medicine and cellular therapy markets. We believe that this is the first such program offered commercially and meets a critical need for the advancement of the regenerative and cellular therapy markets,” said Anthony Dudzinski, the Company’s COO. “Now there is a way for physicians to assess their own performance without the need to overcome the significant costs of purchasing and maintaining their own testing facilities.”

The new testing services are offered by ACS Laboratories reflects the Company’s increasing branding and commercialization of products and services developed around its proprietary clinical tissue processing and storage methodologies. ACS Laboratory incorporates its proprietary cGMP/cGTP aseptic methods and FDA guidance’s into these services to ensure the highest quality and most useful information for physicians.

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing services and patented products for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. The Company’s clinical processing, patented cell culture media products and cellular preservation platform supports the science and regenerative medicine applications being developed globally. The Company provides the highest quality, clinically processed cells assuring their purity, viability and growth capabilities, while at the same time developing cutting edge applications, therapies and patented laboratory products and services for consumer and commercial applications.

“We anticipate that the combination of American CryoStem’s patented technology with PGen’s intellectual property will create tremendous opportunities in the medical device and wound healing markets. Our mutual goal is to create unique, high performance applications for the rapidly growing regenerative medicine market,” says Burt Ensley PhD., PGen’s CEO.

John Arnone, CEO of American CryoStem, stated, “Discussions have been underway for some time and this formalized collaborative agreement is Phase I of combining these two unique patented technologies. This collaboration is part of the Company’s efforts to leverage its clinical laboratory processes into the cellular therapy and regenerative medicine application market. We continuously seek collaborators with patented technologies that can be combined with our clinical technologies and patented products. To encourage collaboration, our agreement is designed for both companies to share the intellectual property rights developed.”

About Protein Genomics, Inc: Protein Genomics is headed by Dr. Burt Ensley, an Amgen alumni, and former Board member of the National Science Foundation’s BIO Directorate. Dr. Ensley holds 19 issued patents in molecular biology. Protein Genomics produces refined biomaterials using gene synthesis, engineering design and fermentation manufacturing. Dr. Ensley is currently on the adjunct faculties of the University of Arizona and Northern Arizona University, and serves as Chairman and CEO of Dermaplus, Inc.

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing services and patented products for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. The Company’s clinical processing, patented cell culture media products and cellular preservation platform supports the science and regenerative medicine applications being developed globally. The Company provides the highest quality, clinically processed cells assuring their purity, viability and growth capabilities, while at the same time developing cutting edge applications, therapies and patented laboratory products and services for consumer and commercial applications.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. American CryoStem’s decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM’s support of policy efforts toward safe and reliable cellular products.

Morrie Ruffin, Managing Director for the Alliance for Regenerative Medicine, commented, “We are delighted to have American CryoStem as part of the Alliance and look forward to working together to advance the field of adipose-derived stem cells for a variety of therapeutic applications.”

ARM’s membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research and other organizations supporting regenerative medicine. American CryoStem has created and commercialized core proprietary products and platforms for processing, storing and quality management of adipose tissue and adipose derived adult stem cells that are broadly relevant to ARM’s membership.

“American CryoStem is committed to working with industry organizations to develop cutting edge adipose tissue based treatments and therapies. One unique component of our clinical laboratory product and service suite is offering individuals the opportunity to cryogenically store their younger, healthier adult stem cells for their own future use in regenerative medicine,” stated John Arnone, American CryoStem CEO. “We are pleased and honored to work with the Alliance for Regenerative Medicine to educate the public and regulators on the safe uses of adult stem cells and their potential life changing applications.”

In support of these goals, the Company recently launched ACS Laboratories, thus expanding its clinical processing technology to companies, institutions and medical professionals. ACS Laboratories offers a wide range of adipose tissue specific services. Through ACS laboratories patented ACSelerate™ cell culture media, a ten product suite, American CryoStem can leverage its technology and products to participate in a broad range of clinical application opportunities.

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing products and services for adipose (fat) tissue and adipose derived adult stem cells. CRYO’s clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

The study involves researching the regenerative function of a conditioned medium obtained from each participant’s adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing.

John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, “CRYO’s patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility.”

The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician’s office and sent to CRYO’s laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products.

“We are very excited to announce our service agreement and participation in this clinical study for Personal Cell Sciences. This contractual manufacturing agreement reinforces our capabilities to provide CRYO’s exceptional clinical processing for relevant adult stem cell related products,” said Anthony Dudzinski, COO of American CryoStem. “We look forward to our continued business relationship with PCS and expanding these services to other developers to speed their product’s time to market.”

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing products and services for Adipose (fat) Tissue and Adipose Derived Adult Stem Cells. CRYO’s clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

For More Information, contact:
Investor Relations
American CryoStem Corporation
188 East Bergen Place, Suite 204
Red Bank, NJ 07701
Phone:732-747-1007
www.americancryostem.com

The new website experience is centered on providing the consumer simple, easy to read information about Adult Stem Cells and CRYO’s long term adult stem cell storage service currently offered through a national network of physicians. “The decision to redesign the website to be more consumer friendly was an easy decision after CRYO’s successful media campaign launch that attracted over 11,000 new members. From the feedback we received, we knew it was time for an update,” explains Natalia Drulle, Creative Director.

As part of CRYO’s on-going marketing campaign the new site features a live chat function to answer questions concerning the Company’s products and services. “Adding this dynamic feature to the site experience is a useful tool to increase customer support and sales conversion,” says John DiFolco, Director of Marketing. “Our goal is to shorten the sales process and provide instant support as we participate in the Regenerative Medicine market where Adult Stem Cells are frequently the main focus of discussion.”

John Arnone, CEO, stated, “The launch of our new website is another step in offering our products and services directly to the consumer market. Having the ability to educate our clients and then refer them to participating physicians allows us to efficiently deliver our message to targeted areas of the country where our service is being adopted.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult Stem Cells treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells (ADSCs) and Adipose Tissue (AT) for autologous use.

As of January 2012 we have branded our adipose tissue processing facility “ACS Laboratory Services.” This new branding reflects the Company’s increasing commercialization of products and services developed for its proprietary clinical tissue processing methodologies. We have begun offering the first of these products for sale and license which are based on our granted patent (Cell Culture Media, Kits and Methods of Use,” (US 7,898,205 B2)). The product line is the first patented culture, growth and differentiation media specifically designed for use with adipose derived stem cells (ADSC) and is ideally suited for the conversion of new ADSC therapies from research to clinical application. The media is available in both research and clinical grade, in 100ml to 1 liter ready to use quantities. The product line includes undifferentiated growth media, and adipogenic, chondrogenic, and osteogenic differentiation media. The clinical grade media are free from animal (xenomorphic) serum and additives which make them ideally suited for the expansion and differentiation of ADSCs intended for clinical use.

We made our first commercial sale of our media products this month and have begun marketing to increase industry recognition and sales. We currently have a new website www.acslaboratories.com under construction to support this new product offering and all future products and services commercialized by ACS Laboratories.

David Moscatello, Chief Scientist, stated, “I am very excited to have begun offering these products to my colleagues working with ADSCs and believe that these products will assist them in the acceleration of their treatment development. We have additional products and services in various stages of development based on our patented technologies and core adipose tissue processing platform that will be unveiled during the coming year.”

John S. Arnone, CEO, stated, “We are very enthusiastic to be able to announce the commercialization and initial sales revenue from products developed from our recently issued patent. During 2011 we have been the beneficiary of increased dialogue and involvement from both doctors and researchers regarding our services and products under development. Our overall philosophy concerning the services offered by ACS Laboratories is to offer clinical grade products that are free from animal materials that can relieve some of the costs and the significant and increasing regulatory burdens for developers of cellular technologies. These burdens are evidenced in the U.S. Department of Health and Human Services and the FDA’s regulations and guidance for manufacturers and developers in relation to the inclusion of xenomorphic (animal) material in the manufacturing and marketing of new and existing cellular products.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult Stem Cells treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells (ADSCs) and Adipose Tissue (AT) for autologous use.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties.

These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

I hear a lot of baby boomers (of which I am one) talk about aging and the quest to maintain their youthful look, mind and health. If only there was a magic elixir for the myriad problems we face in our advancing age. Well, perhaps there is something that can turn back the hands of time to some extent, a little bit of the fountain of youth if you will.

Adipose tissue has been found to be an easily accessible, abundant source of adult stem cells. These stem cells can be used to treat a broad range of medical and cosmetic conditions. If you look at our Resource Library, you’ll see a sampling of the potential applications of adipose derived stem cells, from growing new bone to aiding reconstructive procedures to mitigating the symptoms of multiple sclerosis. And, yes, adipose derived stem cells can help us look youthful too. You can have lipofilling and lipostructuring performed anywhere on your body. Isn’t this a dream come true? Take your fat from a place you don’t want it and put it somewhere you do! Who of us wouldn’t like to remove a few pounds of avoir du pois and apply it elsewhere?

All joking aside, the potential future medical applications for adipose derived stem cells are profound, and they are not that far off. Now is the dawn of the era of regenerative and personalized medicine. Most countries outside of the United States are already using adult stem cells to treat patients with myocardial infarctions, fistulizing Crohn’s disease, and to grow organs. Medical tourism, traveling to other countries to take advantage of treatments not yet routinely available in the United States, has become a booming industry in part because of regenerative and personalized medicine. It is only a matter of time before these therapies become available in the U.S.

So this brings to mind a question. What can I do now to prepare? Speaking for myself, I already have an answer. I will store my adult stem cells in the hope of using them later in the event of a medical ailment, or, in a more vain moment, when I want to reverse the visible “hands of time” with a cosmetic treatment. Not only will I store my own adult stem cells, but I will encourage my children to store theirs as well. After all, that one umbilical cord blood sample I keep may not be useful for all three of them, so why leave anything to chance? It is a bio-insurance that will give me some peace of mind as a mother. It is also a gift I will be giving to family and loved ones. What about you?

Angela M. Miele, DPM
Medical Science Liaison
American CryoStem

American CryoStem Corporation (the “Company”) has been awarded U.S. Patent Number 7,989,205, entitled “Cell Culture Media, Kits, and Methods of Use” (the “Patent”), by the USPTO. This Patent covers a unique product for cellular growth in the processing of adult stem cells. This is significant to the Company for the advancement of its research, clinical and cosmetic applications. The Company’s management believes that the Patent will support the Company’s efforts in its goal to establish itself as a leader in the preparation of autologous stem cells for use in regenerative medicine. The Patent includes a specific human formulation to overcome the concerns and issues prevalent in the FDA’s and other regulatory agencies’ guidance when using non-human biologic materials in the preparation of stem cells for human use.

John S Arnone, CEO, stated, “We are pleased to have the Patent granted to the Company by the USPTO. We believe the Patent will be instrumental to the industry based on its cellular growth properties and absence of non-human biologic material. Further, as stem cell and regenerative medicine advances in the United States, as it has globally, the Company is confident the Patent, together with our core technology and our intellectual property regarding methods, formulations, devices and products will allow us to enter into additional partnerships and collaborations with other industry participants. The Patent validates our corporate direction and enhances our strategy to obtain strong intellectual property protection.”

Anthony Dudzinski, COO, stated, “We believe the Patent on specie specific media gives the Company a unique market position by alleviating the significant regulatory requirements associated with products containing fetal bovine serum or other non-human biologic components. The Patent is important and will accelerate the development and commercialization of additional Company products and services. We are excited and very optimistic regarding our place in the stem cell industry and the value of our products and services.”

About American CryoStem: The Company markets a core clinical processing platform for Adipose (fat) Derived Adult Stem Cells. The Company’s services provide for the collection, processing, and cryopreservation (long term storage) of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in personalized and regenerative medicine at an affordable price. Adult stem cell treatments are currently being utilized to potentially heal one’s own body of diseases and chronic conditions. The Company’s proprietary platform provides streamlined and affordable processing and cryopreservation of Adipose Derived Stem Cells and Adipose Tissue for autologous (self) use.

Modern medicine and technology (e.g. dialysis, left ventricular assist devices) can keep patients alive longer than was possible fifty years ago, but at what cost? Do these options prolong the hope of a transplant, or accentuate the need for other alternatives?

Organ donations are encouraged in a variety of forms. You can now check a box off on the back of your license plate indicating your willingness to donate your organs should you die in an accident. Living wills allow an individual to direct what organ(s) one would like to donate should you be in a vegetative or non-resuscitable state. Why then, are donations not meeting the current need? Perhaps it is fear of the unknown – there are urban myths, (some heard from patients) – who are concerned that if they have registered as a donor and come to be in a vegetative state, it may hasten a decision leading to their demise. More grass root efforts should be made to raise awareness of organ donation. How many times while in your neighborhood have you seen flyers in a store, for example, asking individuals to get tested as a possible donor for a child or adult who needs a rare bone marrow match or organ transplant? We have the science and technology to perform these complex surgeries, yet thousands die each year in wait. These flyers are a cry for better alternatives, a silent prayer for solutions to unmet needs.

The near-future landscape is ripe to solve this dilemma – an organ created from your own adult stem cells would obviate the need for a donor. It may seem that I am getting ahead of myself, but this scenario is not that far-off. Consider Dr. Anthony Atala, Director of Regenerative Medicine at Wake Forest University, North Carolina. He has already grown human bladders from stem cells taken from the patient and transplanted. All of the recipients are doing well five years later. In addition, he and his team are also “growing” heart valves, muscle, and fingers for future transplantation. He is one of many scientists/clinicians around the world dedicated to tissue engineering using adult stem cells. Those of us who keep tabs on Regenerative Medicine are acutely aware of how close this is, that the finish line is in sight. More studies need to be performed on larger scales, yes, but adult stem cells are providing hope. While not the panacea for all transplant needs, adult stem cells can certainly increase the number of survivors on the waiting list. Even if it is by one, it is a victory against death.

Currently, autologous adult stem cell treatments are being investigated and are showing great promise in many applications; in the very near future one can theoretically heal oneself. There are also early clinical trials showing that adipose derived stem cells may be used for allogeneic transplants. While these are a little further off, they are still plausible. Adult stem cells can now be banked for future therapies as well as current applications should the need arise. This limbo that exists, this game of chance, may have resolution before the end of the decade.
So, for now, we are in a holding pattern – waiting, hoping, anticipating a time when we can tell our patients that the cure for their ailment lies within them.

Angela M. Miele, DPM
Medical Science Liaison
American CryoStem